Lithium augmentation of antidepressants in treatment-refractory depression

Stacey Heit, Charles Nemeroff

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The use of lithium to convert antidepressant nonresponders to responders is reviewed. Although there is little doubt that lithium is effective in a sizable percentage of patients who do not respond to tricyclic antidepressants (TCAs) and serotonin selective reuptake inhibitors (SSRIs), much remains obscure about this effect. Does it work preferentially on antidepressants that act primarily on serotonergic neurons, or is it equally effective with agents that act upon other neurotransmitter systems? When should lithium, compared with other strategies, be utilized in antidepressant nonresponders? Are certain subtypes of depression more likely than others to respond to lithium augmentation? The available literature highlights the efficacy of lithium as an augmenting agent in refractory depression and serves as an impetus for additional neurobiological and clinical studies of this phenomenon.

Original languageEnglish
Pages (from-to)28-34
Number of pages7
JournalJournal of Clinical Psychiatry
Volume59
Issue numberSUPPL. 6
StatePublished - Jul 18 1998
Externally publishedYes

Fingerprint

Treatment-Resistant Depressive Disorder
Lithium
Antidepressive Agents
Serotonergic Neurons
Therapeutics
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Neurotransmitter Agents
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Lithium augmentation of antidepressants in treatment-refractory depression. / Heit, Stacey; Nemeroff, Charles.

In: Journal of Clinical Psychiatry, Vol. 59, No. SUPPL. 6, 18.07.1998, p. 28-34.

Research output: Contribution to journalArticle

@article{f18598da020c435a8477ce3bdc428489,
title = "Lithium augmentation of antidepressants in treatment-refractory depression",
abstract = "The use of lithium to convert antidepressant nonresponders to responders is reviewed. Although there is little doubt that lithium is effective in a sizable percentage of patients who do not respond to tricyclic antidepressants (TCAs) and serotonin selective reuptake inhibitors (SSRIs), much remains obscure about this effect. Does it work preferentially on antidepressants that act primarily on serotonergic neurons, or is it equally effective with agents that act upon other neurotransmitter systems? When should lithium, compared with other strategies, be utilized in antidepressant nonresponders? Are certain subtypes of depression more likely than others to respond to lithium augmentation? The available literature highlights the efficacy of lithium as an augmenting agent in refractory depression and serves as an impetus for additional neurobiological and clinical studies of this phenomenon.",
author = "Stacey Heit and Charles Nemeroff",
year = "1998",
month = "7",
day = "18",
language = "English",
volume = "59",
pages = "28--34",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Lithium augmentation of antidepressants in treatment-refractory depression

AU - Heit, Stacey

AU - Nemeroff, Charles

PY - 1998/7/18

Y1 - 1998/7/18

N2 - The use of lithium to convert antidepressant nonresponders to responders is reviewed. Although there is little doubt that lithium is effective in a sizable percentage of patients who do not respond to tricyclic antidepressants (TCAs) and serotonin selective reuptake inhibitors (SSRIs), much remains obscure about this effect. Does it work preferentially on antidepressants that act primarily on serotonergic neurons, or is it equally effective with agents that act upon other neurotransmitter systems? When should lithium, compared with other strategies, be utilized in antidepressant nonresponders? Are certain subtypes of depression more likely than others to respond to lithium augmentation? The available literature highlights the efficacy of lithium as an augmenting agent in refractory depression and serves as an impetus for additional neurobiological and clinical studies of this phenomenon.

AB - The use of lithium to convert antidepressant nonresponders to responders is reviewed. Although there is little doubt that lithium is effective in a sizable percentage of patients who do not respond to tricyclic antidepressants (TCAs) and serotonin selective reuptake inhibitors (SSRIs), much remains obscure about this effect. Does it work preferentially on antidepressants that act primarily on serotonergic neurons, or is it equally effective with agents that act upon other neurotransmitter systems? When should lithium, compared with other strategies, be utilized in antidepressant nonresponders? Are certain subtypes of depression more likely than others to respond to lithium augmentation? The available literature highlights the efficacy of lithium as an augmenting agent in refractory depression and serves as an impetus for additional neurobiological and clinical studies of this phenomenon.

UR - http://www.scopus.com/inward/record.url?scp=0031809665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031809665&partnerID=8YFLogxK

M3 - Article

C2 - 9674934

AN - SCOPUS:0031809665

VL - 59

SP - 28

EP - 34

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 6

ER -